-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ACD-856 in Depression
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ACD-856 in Depression report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ACD-856 in Depression Drug Details: ACD-856 is under development for the treatment of...
-
Product Insights
Traumatic Brain Injury – Drugs In Development, 2023
Global Markets Direct’s, ‘Traumatic Brain Injury - Drugs In Development, 2023’, provides an overview of the Traumatic Brain Injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for Traumatic Brain Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NN-9499 in Non-Alcoholic Steatohepatitis (NASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NN-9499 in Non-Alcoholic Steatohepatitis (NASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.NN-9499 in Non-Alcoholic Steatohepatitis (NASH)Drug Details:NN-9499 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ACD-440 in Neuropathic Pain (Neuralgia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ACD-440 in Neuropathic Pain (Neuralgia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ACD-440 in Neuropathic Pain (Neuralgia) Drug Details:ACD-440 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – E-602 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - E-602 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.E-602 in Non-Small Cell Lung Cancer Drug Details:E-602 is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ACD-856
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry ACD-856 Drug Details ACD-856 is under development for the treatment of Alzheimer's disease, sleeping...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ACD-440
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry ACD-440 Drug Details ACD-440 is under development for the treatment of neuropathic pain including...
-
Product Insights
Parkinson’s Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Parkinson's disease (PD) is a neurodegenerative disorder characterized by movement dysfunctions. The main finding in brains of people with PD is loss of dopaminergic neurons in substantia nigra. Symptoms generally develop slowly over years. People with PD experience dyskinesia, dystonia, tremor, stiffness and impaired locomotory functions. Risk factors include age, genetic factors, environmental factors and gender. Treatment options include anticholinergics, COMT inhibitors and dopamine agonists. The Parkinson’s disease pipeline drugs market research report provides comprehensive information on the therapeutics under...
-
Product Insights
Osteoarthritis Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Osteoarthritis Pain Pipeline Drugs Market Overview Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoarthritis Pain – Drugs In Development, 2022, provides an overview of the Osteoarthritis Pain (Central Nervous System) pipeline landscape. Osteoarthritis Pain Pipeline Drugs Market is the most common symptom associated with osteoarthritis which causes disruption of the cartilage. If the condition worsens, it leads to rubbing of the bones against each other causing even more pain and loss of movement. Risk factors are age, joint...
-
Product Insights
Traumatic Brain Injury Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Traumatic brain injury happens when an external mechanical force causes brain damage. Traumatic brain injury usually results from a violent blow or jolt to the head or body. Symptoms include headache, dizziness, nausea or vomiting, mood changes, fatigue or drowsiness, difficulty sleeping, and memory or concentration problems. Risk factor includes age. Certain types of traumatic brain injury increase the risk of developing Alzheimer's disease and coordination problems. The traumatic brain injury drugs in development market research report provides an overview...